← Back to Search

Advance Care Planning Intervention for Blood Cancers (APP SICP Trial)

N/A
Recruiting
Led By Kah Poh Loh
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥60 years
Being managed in the inpatient setting
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years following their participation in the study or death
Awards & highlights

APP SICP Trial Summary

This trial will test whether a specific advance care planning intervention delivered by an APP can improve outcomes for older patients with AML or MDS.

Who is the study for?
This trial is for patients aged 60 or older who have been diagnosed with acute myeloid leukemia (AML) or high/very high risk myelodysplastic syndromes (MDS), as defined by the IPSS-R. Participants must be able to understand and speak English, provide informed consent, and currently be receiving care in a hospital.Check my eligibility
What is being tested?
The study is testing an inpatient serious illness care program designed specifically for older adults with blood cancers. The goal is to see how effective this intervention is at improving advance care planning among these patients.See study design
What are the potential side effects?
Since the intervention involves advance care planning rather than medical treatment, there are no direct physical side effects associated with it. However, discussing serious illness may cause emotional or psychological discomfort.

APP SICP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 60 years old or older.
Select...
I am currently being treated as a hospital inpatient.

APP SICP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years following their participation in the study or death
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years following their participation in the study or death for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Completion of advance directives
Secondary outcome measures
End of life quality indicators

APP SICP Trial Design

1Treatment groups
Experimental Treatment
Group I: ExperimentalExperimental Treatment1 Intervention
Patients will participate in an inpatient advance care planning intervention.

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
834 Previous Clinical Trials
518,242 Total Patients Enrolled
Kah Poh LohPrincipal InvestigatorUniversity of Rochester
5 Previous Clinical Trials
260 Total Patients Enrolled

Media Library

Inpatient serious illness care program Clinical Trial Eligibility Overview. Trial Name: NCT05433090 — N/A
Blood Cancers Research Study Groups: Experimental
Blood Cancers Clinical Trial 2023: Inpatient serious illness care program Highlights & Side Effects. Trial Name: NCT05433090 — N/A
Inpatient serious illness care program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05433090 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any enrollment opportunities available for this experiment?

"According to the data hosted on clinicaltrials.gov, this medical study is actively seeking applicants. This trial was initially announced on September 6th 2022 and updated most recently on November 7th 2022."

Answered by AI

What is the scope of individuals involved in this clinical investigation?

"Affirmative, clinicaltrials.gov affirms that this medical examination is actively registering participants since its inception on September 6th 2022. It was last updated the 7th of November and requires 50 subjects from 1 site to finish."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
How old are they?
65+
What site did they apply to?
University of Rochester
What portion of applicants met pre-screening criteria?
Met criteria
~14 spots leftby Nov 2024